profit from every $100 of sales.
$0$100
Stereotaxis
$1.14+4.59% today
-58.1% in 1 year
1-year low $0.841-year high $2.85
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Stereotaxis sold, what it kept, and what it did with the cash.
Sales went from $28.1 million in 2022 to $32.4 million in 2025, with -$21.6 million of profit last year.
SalesProfit
Stereotaxis vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Stereotaxis | No profit yet | ||
 ResMed | 21.8× · Fair price | ||
 West Pharmaceutical Services | 58.3× · Expensive | ||
 Hologic | 30.0× · Fair price | ||
 Baxter International | No profit yet |
AI analysis
An AI analyst reads Stereotaxis's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 28 | 27 | 27 | 32 | |
| 18 | 15 | 15 | 17 | |
| -19 | -22 | -25 | -22 | |
| -18 | -21 | -24 | -21 | |
| -18 | -21 | -24 | -22 | |
| -0.26 | -0.27 | -0.30 | -0.25 | |
| 65.6% | 55.5% | 54.2% | 52.7% | |
| -66.7% | -81.6% | -91.9% | -68.3% | |
| -65.0% | -77.4% | -89.3% | -66.8% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 53 | 42 | 47 | 52 |
| Cash | 9 | 20 | 12 | 13 |
| Total debt | 6 | 5 | 6 | 5 |
| Total liabilities | 21 | 20 | 35 | 34 |
| 32 | 22 | 11 | 19 | |
| 76 | 81 | 85 | 91 | |
| -39.3% | -62.9% | -112.1% | -72.3% | |
| -57.3% | -94.5% | -210.3% | -115.6% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -8 | -9 | -8 | -14 | |
| 2 | 0 | 0 | 0 | |
| -11 | -10 | -9 | -14 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 11 | 11 | 10 | 10 |
Valuation
- –
- –
- –
- 9.3×
- 3.5×
- –
- –
- -12.1%
- -18.9%
- 0.0%
Profitability
- 52.7%
- -68.3%
- -66.8%
- -62.6%
- -67.6%
- -75.0%
- -153.2%
- -40.1%
- -69.0%
- 30.2%
Growth
- +4.8%
- –
- −61.5%
- –
- +4.7%
Financial health
- -0.4×
- 0.27
- 9.8%
- –
- 1.55
- 1.10
- 0.58
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 3%of 948
Bottom 6%of 871
Bottom 27%of 868
Bottom 9%of 985
What analysts expect
- Average price target
- $4.00
- Range
- $4.00 – $4.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 12, 2026 | -0.03 | -0.04 | +25.0% |
| Mar 9, 2026 | -0.06 | -0.06 | +0.0% |
| Nov 11, 2025 | -0.03 | -0.06 | +50.0% |
| Aug 7, 2025 | -0.05 | -0.07 | +28.6% |
| May 12, 2025 | -0.07 | -0.07 | +0.0% |
| Mar 3, 2025 | -0.09 | -0.06 | −50.0% |
| Nov 11, 2024 | -0.08 | -0.05 | −60.0% |
| Aug 12, 2024 | -0.07 | -0.05 | −33.3% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
27No pass
Benjamin Graham
27No pass
Philip Fisher
30No pass
Peter Lynch
34No pass
Joel Greenblatt
0No pass
Charlie Munger
29No pass
Terry Smith
26No pass
Questions about Stereotaxis
Is Stereotaxis a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Stereotaxis AI analysis
What does Stereotaxis do?
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. It is in Medical - Instruments & Supplies.
Does Stereotaxis pay a dividend?
No. Stereotaxis does not pay a dividend at the moment.
Is Stereotaxis stock halal?
Yes. Stereotaxis passes our halal screen: its business is permitted and its debt is 5% of its market value, under the 30% limit. How we check
How has Stereotaxis stock done over the past year?
Down 58.1% over the past twelve months, to $1.14. It traded between $0.84 and $2.85 and is 60.0% below its high.
Who are Stereotaxis's competitors?
The largest listed companies in the same industry are ResMed, West Pharmaceutical Services, Hologic and Baxter International. The peers table on this page compares their profit, growth and price with Stereotaxis's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.